Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER

NCT07489066 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07489066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07489066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2026
Completion date
July 30, 2031
Enrollment
120 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, carcinoma, non-small-cell lung (nsclc), lung cancer (nsclc), lung disease, lung neoplasms, non-small cell lung cancer, non-small cell lung cancer, non-squamous, non-small cell lung cancer, squamous, non-small-cell lung